FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma, Breyanzi
By Lori Solomon HealthDay Reporter
MONDAY, March 18, 2024 -- The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The expanded approval for the one-time personalized infusion is for adults who have received at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTKi) and a B-cell lymphoma 2 inhibitor (BCL2i). Boxed warnings for Breyanzi include risks for cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies.
The accelerated approval was based on response rate and duration of response in the TRANSCEND CLL 004 study, the first pivotal multicenter trial to evaluate a CAR T-cell therapy in patients with relapsed or refractory CLL or SLL. The results of the phase 1/2 trial of 89 patients indicated a complete response rate of 20 percent with Breyanzi treatment. For those achieving a complete response, the median duration of response was not yet reached. The overall response rate was 45 percent, with a median duration of response of 35.3 months. Across patients treated with Breyanzi who achieved a complete response, the minimal residual disease negativity rate was 100 percent in the blood and 92.3 percent in the bone marrow.
"The FDA approval of liso-cel in relapsed or refractory CLL and SLL after treatment with prior BTKi and BCL2i is a remarkable breakthrough, shifting the treatment paradigm from continuous therapy with sequential regimens to overcome drug resistance, to a one-time personalized T-cell based approach that has the potential to offer patients complete and lasting remission," lead investigator Tanya Siddiqi, M.D., from the City of Hope National Medical Center in Duarte, California, said in a statement.
Approval of Breyanzi was granted to Bristol Myers Squibb.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
THURSDAY, April 25, 2024 -- For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by...
Ending Specialized Follow-Up Feasible in Asymptomatic, Low-Risk Leukemia
THURSDAY, April 18, 2024 -- For select patients with asymptomatic, lower-risk chronic lymphocytic leukemia, ending specialized follow-up (sFU) is feasible and safe, according to a...
Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients
THURSDAY, March 21, 2024 -- For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.